What is HC Wainwright’s Forecast for TRVI Q1 Earnings?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Trevi Therapeutics in a note issued to investors on Wednesday, March 18th. HC Wainwright analyst B. Folkes expects that the company will earn ($0.08) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.17) EPS and FY2030 earnings at $0.79 EPS.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04.

Several other research firms have also issued reports on TRVI. Needham & Company LLC raised their price target on shares of Trevi Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday. Stifel Nicolaus upped their price objective on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Leerink Partners increased their target price on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. D. Boral Capital reissued a “buy” rating and set a $19.00 target price on shares of Trevi Therapeutics in a research report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $21.33.

Trevi Therapeutics Price Performance

NASDAQ:TRVI opened at $10.69 on Thursday. Trevi Therapeutics has a one year low of $4.85 and a one year high of $14.39. The company has a fifty day moving average price of $11.15 and a 200 day moving average price of $10.93. The stock has a market cap of $1.37 billion, a P/E ratio of -33.41 and a beta of 0.94.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Trevi Therapeutics by 4.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company’s stock worth $195,000 after acquiring an additional 911 shares during the period. Ameritas Investment Partners Inc. increased its stake in Trevi Therapeutics by 20.5% in the third quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company’s stock valued at $70,000 after acquiring an additional 1,300 shares during the period. Kennedy Capital Management LLC raised its position in Trevi Therapeutics by 2.4% in the fourth quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company’s stock worth $704,000 after purchasing an additional 1,336 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Trevi Therapeutics by 32.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock worth $78,000 after purchasing an additional 1,523 shares in the last quarter. Finally, BIT Capital GmbH lifted its stake in Trevi Therapeutics by 32.0% during the third quarter. BIT Capital GmbH now owns 6,739 shares of the company’s stock worth $62,000 after purchasing an additional 1,633 shares during the period. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trending Headlines about Trevi Therapeutics

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Needham raised its price target from $22 to $24 and maintained a “buy” — a bullish signal implying substantial upside to current levels. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating with a $19 target, supporting demand from the buy-side. Read More.
• Positive Sentiment: Trevi achieved FDA alignment and plans two pivotal Phase III trials for IPF‑related chronic cough — a major pipeline and de‑risking milestone that materially increases the program’s commercial potential. Read More.
• Positive Sentiment: Q4 results showed EPS of ($0.06), beating consensus (−$0.10), and management provided business updates tied to the Phase 3 plan — supportive near-term fundamentals. Read More.
• Neutral Sentiment: Analyst/market write-ups are re‑examining TRVI valuation after the FDA alignment; these pieces can help inform longer‑term upside but don’t change near‑term cash/clinical timelines. Read More.
• Negative Sentiment: Morgan Stanley trimmed its price target from $19 to $18 while keeping an “overweight” rating — a modest downgrade to upside expectations that may have tempered buying enthusiasm. Read More.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.